Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX
Amylyx Pharmaceuticals stock price today
$7.84
+3.96
+102.58%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Amylyx Pharmaceuticals stock price monthly change
+79.17%
month
Amylyx Pharmaceuticals stock price quarterly change
+79.17%
quarter
Amylyx Pharmaceuticals stock price yearly change
-73.40%
year
Amylyx Pharmaceuticals key metrics
Market Cap | 276.24M |
Enterprise value | 1.85B |
P/E | -8.51 |
EV/Sales | 83.63 |
EV/EBITDA | -9.64 |
Price/Sales | 86.16 |
Price/Book | 5.62 |
PEG ratio | 0.07 |
EPS | -1.03 |
Revenue | 398.00M |
EBITDA | -80.07M |
Income | -71.09M |
Revenue Q/Q | 24.10% |
Revenue Y/Y | 324.95% |
Profit margin | -892.38% |
Oper. margin | -905.72% |
Gross margin | 86.54% |
EBIT margin | -905.72% |
EBITDA margin | -20.12% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmylyx Pharmaceuticals stock price history
Amylyx Pharmaceuticals stock forecast
Amylyx Pharmaceuticals financial statements
Average Price Target
$8.25
Potential upside: 5.22%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 98.21M | 22.07M | 22.47% |
|---|---|---|---|
| Sep 2023 | 102.69M | 20.89M | 20.35% |
| Dec 2023 | 108.44M | 4.73M | 4.36% |
| Mar 2024 | 88.64M | -118.79M | -134.01% |
| 2024-05-09 | 0.24 | -0.46 |
|---|
| Jun 2023 | 453588000 | 67.22M | 14.82% |
|---|---|---|---|
| Sep 2023 | 466584000 | 48.18M | 10.33% |
| Dec 2023 | 517454000 | 84.02M | 16.24% |
| Mar 2024 | 417457000 | 93.02M | 22.28% |
| Jun 2023 | 8.60M | 123.22M | 1.38M |
|---|---|---|---|
| Sep 2023 | -5.16M | -108.08M | 889K |
| Dec 2023 | 13.55M | 20.92M | 230K |
| Mar 2024 | -489K | 819K | 131K |
Amylyx Pharmaceuticals alternative data
| Aug 2023 | 296 |
|---|---|
| Sep 2023 | 338 |
| Oct 2023 | 338 |
| Nov 2023 | 338 |
| Dec 2023 | 374 |
| Jan 2024 | 374 |
| Feb 2024 | 374 |
| Mar 2024 | 384 |
| Apr 2024 | 384 |
| May 2024 | 384 |
| Jun 2024 | 384 |
| Jul 2024 | 384 |
Amylyx Pharmaceuticals other data
22.16%
-60.84%
of AMLX is owned by hedge funds
73
-57
12.96M
-35.61M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 17210 |
| Feb 2024 | 0 | 2838 |
| Mar 2024 | 0 | 11602 |
| May 2024 | 5000 | 10455 |
| Sep 2024 | 190000 | 57329 |
| Dec 2024 | 0 | 5421 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BEDROSIAN CAMILLE L officer: Chief Me.. | Common Stock | 5,421 | $5.54 | $30,005 | ||
Option | KLEE JUSTIN B. director, officer: Co-Chief Exe.. | Common Stock | 63,690 | $1.57 | $99,993 | ||
Option | KLEE JUSTIN B. director, officer: Co-Chief Exe.. | Stock Option (right to buy) | 63,690 | $1.57 | $99,993 | ||
Sale | KLEE JUSTIN B. director, officer: Co-Chief Exe.. | Common Stock | 18,589 | $3.2 | $59,429 | ||
Sale | COHEN JOSHUA B director, officer: Co-Chief Exe.. | Common Stock | 18,589 | $3.2 | $59,410 | ||
Sale | BEDROSIAN CAMILLE L officer: Chief Me.. | Common Stock | 11,442 | $3.2 | $36,557 | ||
Sale | MAZZARIELLO GINA officer: Chief Legal Officer | Common Stock | 8,709 | $3.2 | $27,843 | ||
Option | COHEN JOSHUA B director, officer: Co-Chief Exe.. | Common Stock | 1,857 | $1.57 | $2,915 | ||
Option | COHEN JOSHUA B director, officer: Co-Chief Exe.. | Stock Option (right to buy) | 1,857 | $1.57 | $2,915 | ||
Option | COHEN JOSHUA B director, officer: Co-Chief Exe.. | Common Stock | 34,449 | $1.57 | $54,085 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector
Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics
Amylyx: A Biotech Underdog's Resilient Performance And Promising Market Potential
Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases
Amylyx: Patient Advocacy, If Not Drug Merit, Will See It Through
Amylyx: Future Looks Good After Surprise Approval, But Unpredictable, Too
-
What's the price of Amylyx Pharmaceuticals stock today?
One share of Amylyx Pharmaceuticals stock can currently be purchased for approximately $7.84.
-
When is Amylyx Pharmaceuticals's next earnings date?
Unfortunately, Amylyx Pharmaceuticals's (AMLX) next earnings date is currently unknown.
-
Does Amylyx Pharmaceuticals pay dividends?
No, Amylyx Pharmaceuticals does not pay dividends.
-
How much money does Amylyx Pharmaceuticals make?
Amylyx Pharmaceuticals has a market capitalization of 276.24M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1612.94% to 380.79M US dollars. Amylyx Pharmaceuticals earned 49.27M US dollars in net income (profit) last year or -$0.46 on an earnings per share basis.
-
What is Amylyx Pharmaceuticals's stock symbol?
Amylyx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AMLX".
-
What is Amylyx Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Amylyx Pharmaceuticals?
Shares of Amylyx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Amylyx Pharmaceuticals have?
As Jul 2024, Amylyx Pharmaceuticals employs 384 workers.
-
When Amylyx Pharmaceuticals went public?
Amylyx Pharmaceuticals, Inc. is publicly traded company for more then 3 years since IPO on 7 Jan 2022.
-
What is Amylyx Pharmaceuticals's official website?
The official website for Amylyx Pharmaceuticals is amylyx.com.
-
Where are Amylyx Pharmaceuticals's headquarters?
Amylyx Pharmaceuticals is headquartered at 43 Thorndike Street, Cambridge, MA.
-
How can i contact Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals's mailing address is 43 Thorndike Street, Cambridge, MA and company can be reached via phone at +61 76820917.
-
What is Amylyx Pharmaceuticals stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Amylyx Pharmaceuticals in the last 12 months, the avarage price target is $8.25. The average price target represents a 5.22% change from the last price of $7.84.
Amylyx Pharmaceuticals company profile:
Amylyx Pharmaceuticals, Inc.
amylyx.comExchange:
NASDAQ
Full time employees:
384
Industry:
Biotechnology
Sector:
Healthcare
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
43 Thorndike Street
Cambridge, MA 02141
Cambridge, MA 02141
CIK: 0001658551
ISIN: US03237H1014
CUSIP: 03237H101
